Transmembrane proteins (TPs) in their full-length and biologically active form presents challenges in purification primarily due to their innate complex structures. To overcome the challenges of expressing TPs, the FLAG technology from Acrobio addresses their protein expression knowledge to provide highly bioactive, stabilized, native full-length multi-pass transmembrane target antigens for the development of immune-related targeted therapeutics.
During this talk we discuss:
- How to overcome the challenges in transmembrane proteins (TPs) expression
- The capabilities of the FLAG technology from Acrobio
